NCT01412957 · BASELINE

Baseline characteristics

Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer · Source last updated 2017-03-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
189
group Id
BG001
value
188
group Id
BG002
value
377
units
Participants

groups

description
Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus best supportive care (BSC) until disease progression, withdrawal of consent, death, or intolerance of study drug.
id
BG000
title
Panitumumab + BSC
description
Participants received best supportive care until disease progression, withdrawal of consent, or death.
id
BG001
title
BSC Alone
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
spread
10.7
value
60.2
group Id
BG001
spread
11.1
value
58.7
group Id
BG002
spread
10.9
value
59.4
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
82
group Id
BG001
value
79
group Id
BG002
value
161
title
Female
measurements
group Id
BG000
value
107
group Id
BG001
value
109
group Id
BG002
value
216
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
23
group Id
BG001
value
22
group Id
BG002
value
45
title
Hispanic or Latino
categories
measurements
group Id
BG000
value
166
group Id
BG001
value
166
group Id
BG002
value
332
title
Not Hispanic or Latino
param Type
NUMBER
title
Race/Ethnicity, Customized
unit Of Measure
participants
classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
3
group Id
BG002
value
3
title
American Indian or Alaska Native
categories
measurements
group Id
BG000
value
79
group Id
BG001
value
82
group Id
BG002
value
161
title
Asian
categories
measurements
group Id
BG000
value
107
group Id
BG001
value
102
group Id
BG002
value
209
title
White
categories
measurements
group Id
BG000
value
3
group Id
BG001
value
1
group Id
BG002
value
4
title
Other
param Type
NUMBER
title
Race/Ethnicity, Customized
unit Of Measure
participants
classes
categories
measurements
group Id
BG000
value
86
group Id
BG001
value
85
group Id
BG002
value
171
title
Europe
categories
measurements
group Id
BG000
value
80
group Id
BG001
value
82
group Id
BG002
value
162
title
Asia
categories
measurements
group Id
BG000
value
23
group Id
BG001
value
21
group Id
BG002
value
44
title
Rest of world
param Type
NUMBER
title
Geographic Region
unit Of Measure
participants
classes
categories
measurements
group Id
BG000
value
71
group Id
BG001
value
65
group Id
BG002
value
136
title
Grade 0
categories
measurements
group Id
BG000
value
100
group Id
BG001
value
107
group Id
BG002
value
207
title
Grade 1
categories
measurements
group Id
BG000
value
18
group Id
BG001
value
16
group Id
BG002
value
34
title
Grade 2
description
A scale to assess a patient's disease status. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; 2 = Ambulatory and capable of all self care, unable to carry out any work activities. Up and about \> 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.
param Type
NUMBER
title
Eastern Cooperative Oncology Group (ECOG) Performance Status
unit Of Measure
participants
classes
categories
measurements
group Id
BG000
value
108
group Id
BG001
value
106
group Id
BG002
value
214
title
Colon
categories
measurements
group Id
BG000
value
81
group Id
BG001
value
81
group Id
BG002
value
162
title
Rectum
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
Missing
param Type
NUMBER
title
Location of Primary Tumor
unit Of Measure
participants

Complete source fields

denoms

counts
group Id
BG000
value
189
group Id
BG001
value
188
group Id
BG002
value
377
units
Participants

groups

description
Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus best supportive care (BSC) until disease progression, withdrawal of consent, death, or intolerance of study drug.
id
BG000
title
Panitumumab + BSC
description
Participants received best supportive care until disease progression, withdrawal of consent, or death.
id
BG001
title
BSC Alone
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
spread
10.7
value
60.2
group Id
BG001
spread
11.1
value
58.7
group Id
BG002
spread
10.9
value
59.4
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
82
group Id
BG001
value
79
group Id
BG002
value
161
title
Female
measurements
group Id
BG000
value
107
group Id
BG001
value
109
group Id
BG002
value
216
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
23
group Id
BG001
value
22
group Id
BG002
value
45
title
Hispanic or Latino
categories
measurements
group Id
BG000
value
166
group Id
BG001
value
166
group Id
BG002
value
332
title
Not Hispanic or Latino
param Type
NUMBER
title
Race/Ethnicity, Customized
unit Of Measure
participants
classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
3
group Id
BG002
value
3
title
American Indian or Alaska Native
categories
measurements
group Id
BG000
value
79
group Id
BG001
value
82
group Id
BG002
value
161
title
Asian
categories
measurements
group Id
BG000
value
107
group Id
BG001
value
102
group Id
BG002
value
209
title
White
categories
measurements
group Id
BG000
value
3
group Id
BG001
value
1
group Id
BG002
value
4
title
Other
param Type
NUMBER
title
Race/Ethnicity, Customized
unit Of Measure
participants
classes
categories
measurements
group Id
BG000
value
86
group Id
BG001
value
85
group Id
BG002
value
171
title
Europe
categories
measurements
group Id
BG000
value
80
group Id
BG001
value
82
group Id
BG002
value
162
title
Asia
categories
measurements
group Id
BG000
value
23
group Id
BG001
value
21
group Id
BG002
value
44
title
Rest of world
param Type
NUMBER
title
Geographic Region
unit Of Measure
participants
classes
categories
measurements
group Id
BG000
value
71
group Id
BG001
value
65
group Id
BG002
value
136
title
Grade 0
categories
measurements
group Id
BG000
value
100
group Id
BG001
value
107
group Id
BG002
value
207
title
Grade 1
categories
measurements
group Id
BG000
value
18
group Id
BG001
value
16
group Id
BG002
value
34
title
Grade 2
description
A scale to assess a patient's disease status. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; 2 = Ambulatory and capable of all self care, unable to carry out any work activities. Up and about \> 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.
param Type
NUMBER
title
Eastern Cooperative Oncology Group (ECOG) Performance Status
unit Of Measure
participants
classes
categories
measurements
group Id
BG000
value
108
group Id
BG001
value
106
group Id
BG002
value
214
title
Colon
categories
measurements
group Id
BG000
value
81
group Id
BG001
value
81
group Id
BG002
value
162
title
Rectum
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
Missing
param Type
NUMBER
title
Location of Primary Tumor
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice